Trials / Completed
CompletedNCT02073448
Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
A Multicenter, Randomized, Double-blinded, Active-controlled Parallel Group Efficacy and Safety Study of GK530G Versus CD0271 0.1% Gel and CD1579 2.5% Gel in the Treatment of Acne Vulgaris.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 417 (actual)
- Sponsor
- Galderma R&D · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
This study is to demonstrate the superiority in efficacy of the GK530G (fixed combination of CD0271 0.1% and CD1579 2.5%) versus each of the monads (CD0271 0.1% and CD1579 2.5%) in the treatment of acne vulgaris for up to 12 weeks, in the Japanese patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GK530G | |
| DRUG | CD0271 | |
| DRUG | CD1579 |
Timeline
- Start date
- 2014-03-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2014-02-27
- Last updated
- 2017-03-28
- Results posted
- 2016-11-03
Locations
13 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT02073448. Inclusion in this directory is not an endorsement.